Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Conference
Indeed, today, Akero Therapeutics (AKRO) presented virtually at the H.C. Wainwright 7th Annual NASH Conference on Tuesday, October 24, 2023, at 12:00 p.m. E.T.
A live webcast of the fireside chat will be available through the investor relations section of the Company’s website at www.akerotx.com
In case you missed the live webcast, an archived replay will be available on the Company’s website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company.
Akero is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including NASH, a disease without any approved therapies.
Akero’s lead product candidate, EFX, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body.
EFX is designed to offer convenient once-weekly subcutaneous dosing. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated).
Akero is headquartered in South San Francisco. Visit the firm at akerotx.com and follow it on LinkedIn and Twitter for more information.
News & Comments
October 24, 2023
Today at 2 PM, Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Conference
Indeed, today, Akero Therapeutics (AKRO) presented virtually at the H.C. Wainwright 7th Annual NASH Conference on Tuesday, October 24, 2023, at 12:00 p.m. E.T.
A live webcast of the fireside chat will be available through the investor relations section of the Company’s website at www.akerotx.com
In case you missed the live webcast, an archived replay will be available on the Company’s website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company.
Akero is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including NASH, a disease without any approved therapies.
Akero’s lead product candidate, EFX, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body.
EFX is designed to offer convenient once-weekly subcutaneous dosing. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated).
Akero is headquartered in South San Francisco. Visit the firm at akerotx.com and follow it on LinkedIn and Twitter for more information.
Investor Contact:
Austin Murtagh 212.698.8696 [email protected]
Media Contact:
Sarah O’Connell 732.456.0092 [email protected]
Click here to read more about Akero Therapeutics.
Other Articles